Psyence Biomed logo.png
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
October 31, 2024 07:30 ET | Psyence Biomedical Ltd.
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to...
Psyence Biomed logo.png
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
October 24, 2024 07:00 ET | Psyence Biomedical Ltd.
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce...
Psyence Biomed logo.png
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
October 17, 2024 07:00 ET | Psyence Biomedical Ltd.
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic...
Psyence Biomed logo.png
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
October 04, 2024 16:05 ET | Psyence Biomedical Ltd.
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its...
Psyence Biomed logo.png
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
September 19, 2024 07:30 ET | Psyence Biomedical Ltd.
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into a conditional share sale agreement...
Psyence Biomed logo.png
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
September 16, 2024 07:30 ET | Psyence Biomedical Ltd.
  Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use...
Psyence Biomed logo.png
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
September 13, 2024 16:30 ET | Psyence Biomedical Ltd.
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the...
Psyence Biomed logo.png
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
September 09, 2024 07:30 ET | Psyence Biomedical Ltd.
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of naturally derived psilocybin-based therapeutics, today...
Psyence Biomed logo.png
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
September 06, 2024 07:30 ET | Psyence Biomedical Ltd.
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) ...
Psyence Biomed logo.png
Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
September 04, 2024 07:30 ET | Psyence Biomedical Ltd.
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM, PBMWW) (“Psyence Biomed” or the “Company”) today announced that the Company has entered into a worldwide, exclusive...